NASDAQ: $ROIV
BASEL, Switzerland and LONDON and NEW YORK, August 27, 2026 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today announced that the U.S. Food and Drug Administration (FDA) has approved Lisraya (brepocitinib) 30 mg for the treatment of adults with…
Source: Read More